Results
T2DM
The RESET-IT Main trial (ClinicalTrials.Gov NCT02192424) was a multi-centre, parallel arm trial in which adults with T2DM were randomly assigned to receive induction therapy with a 3-week course of IIT, followed by maintenance therapy consisting of either (i) metformin alone or (ii) metformin with intermittent 2-week courses of short-term IIT administered every 3-months for 2-years. As recently reported